Syros Pharmaceuticals Ownership

SYRS Stock

USD 0.29 0.03 11.54%

Syros Pharmaceuticals shows a total of 26.83 Million outstanding shares. The majority of Syros Pharmaceuticals outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Syros Pharmaceuticals to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Syros Pharmaceuticals. Please pay attention to any change in the institutional holdings of Syros Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.

Shares in Circulation

First Issued

2016-09-30

Previous Quarter

39 M

Current Value

39 M

Avarage Shares Outstanding

10.5 M

Quarterly Volatility

12.2 M

Covid

Some institutional investors establish a significant position in stocks such as Syros Pharmaceuticals in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Syros Pharmaceuticals, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Dividends Paid is likely to gain to about 50.8 M in 2024, despite the fact that Dividend Paid And Capex Coverage Ratio is likely to grow to (383.17). Common Stock Shares Outstanding is likely to gain to about 29.7 M in 2024, whereas Net Loss is likely to drop (89.4 M) in 2024.

Market Cap Enterprise Value

Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Syros Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Syros Stock please use our How to Invest in Syros Pharmaceuticals guide.

Syros Stock Ownership Analysis

About 76.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 3.07. Syros Pharmaceuticals had not issued any dividends in recent years. The entity had 1:10 split on the 19th of September 2022. Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. Syros Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 124 people. To find out more about Syros Pharmaceuticals contact Conley Chee at 617 744 1340 or learn more at https://www.syros.com.

Besides selling stocks to institutional investors, Syros Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Syros Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Syros Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Syros Pharmaceuticals Quarterly Liabilities And Stockholders Equity

85 Million

Only 1.37% of Syros Pharmaceuticals are currently held by insiders. Unlike Syros Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Syros Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Syros Pharmaceuticals' insider trades

Syros Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Syros Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Syros Pharmaceuticals backward and forwards among themselves. Syros Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Syros Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.

		Shares
Ubs O'connor Llc	2024-09-30	359.3 K
Exoduspoint Capital Management, Lp	2024-09-30	313 K
Walleye Trading Advisors, Llc	2024-06-30	285.8 K
Goldman Sachs Group Inc	2024-06-30	262.4 K
Blackrock Inc	2024-06-30	259.2 K
Omega Fund Management Llc	2024-09-30	251.3 K
Geode Capital Management, Llc	2024-09-30	204.7 K
Marshall Wace Asset Management Ltd	2024-06-30	160.4 K
Exome Asset Management Llc	2024-06-30	159.2 K
Bain Capital Life Sciences Investors, Llc	2024-09-30	2.8 M
Artal Group S A	2024-06-30	2.5 M

Note, although Syros Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Syros Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Syros Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Syros Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Syros Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

		Quirk Gerald E few days ago Disposition of 46657 shares by Quirk Gerald E of Syros Pharmaceuticals at 0.2212 subject to Rule 16b-3
		Fanucci Marsha over two weeks ago Acquisition by Fanucci Marsha of 4000 shares of Syros Pharmaceuticals subject to Rule 16b-3
		Roth David over a month ago Disposition of 6301 shares by Roth David of Syros Pharmaceuticals at 2.22 subject to Rule 16b-3
		Conley Chee over three months ago Disposition of 6004 shares by Conley Chee of Syros Pharmaceuticals at 2.22 subject to Rule 16b-3
		Tyson Timothy over three months ago Acquisition by Tyson Timothy of 4000 shares of Syros Pharmaceuticals subject to Rule 16b-3
		Richard Young over three months ago Disposition of 34837 shares by Richard Young of Syros Pharmaceuticals at 5.12 subject to Rule 16b-3
		Wirth Peter over three months ago Acquisition by Wirth Peter of 6000 shares of Syros Pharmaceuticals at 5.3 subject to Rule 16b-3
		Akkaraju Srinivas over three months ago Disposition of 4000 shares by Akkaraju Srinivas of Syros Pharmaceuticals subject to Rule 16b-3
		Tyson Timothy over three months ago Acquisition by Tyson Timothy of 3856 shares of Syros Pharmaceuticals at 7.07 subject to Rule 16b-3
		David Roth over six months ago Disposition of 10451 shares by David Roth of Syros Pharmaceuticals at 4.95 subject to Rule 16b-3
		Conley Chee over six months ago Disposition of 2000 shares by Conley Chee of Syros Pharmaceuticals subject to Rule 16b-3
		Stephens Kristin over a year ago Exercise or conversion by Stephens Kristin of 17000 shares of Syros Pharmaceuticals subject to Rule 16b-3

Syros Pharmaceuticals Outstanding Bonds

Syros Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Syros Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Syros bonds can be classified according to their maturity, which is the date when Syros Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

	Boeing Co 2196 Corp Bond US097023DG73	View
	SYY 315 14 DEC 51 Corp Bond US871829BR76	View
	SYY 245 14 DEC 31 Corp Bond US871829BQ93	View
	US871829BJ50 Corp Bond US871829BJ50	View
	US871829BK24 Corp Bond US871829BK24	View
	SYSCO P 445 Corp Bond US871829BH94	View
	SYSCO PORATION Corp Bond US871829BN62	View
	SYSCO PORATION Corp Bond US871829BL07	View

View All Syros Pharmaceuticals Corporate Bonds

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Syros Stock Analysis

When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC